Search results
Showing 346 to 360 of 381 results for lung cancer
In development Reference number: GID-TA11800 Expected publication date: TBC
In development Reference number: GID-TA11500 Expected publication date: TBC
Discontinued Reference number: GID-TA11180
We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules (MIB209)
This advice has been updated and replaced by NICE healthtech guidance 611.
NICE has withdrawn this guidance. Takeda will stop marketing mobocertinib (Exkivity) and its marketing authorisation has been withdrawn. Healthcare professionals should discuss alternative treatment options with people currently having mobocertinib.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
In development Reference number: GID-TA11441 Expected publication date: TBC
Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.
In development Reference number: GID-TA11278 Expected publication date: TBC
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
In development Reference number: GID-TA11274 Expected publication date: TBC
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).